Guoyao Shengkang2023Annual Strategic Partner Conference
2023year6month9day-11On the day, Guoyao Shengkang held its first Strategic Partner Conference after the restructuring at the Jinjiang Hotel in Zhujiagou. Nearly50The participants attended the meeting. The session focused on the theme 'Energy Transformation & Co-construction', leading to a series of lively discussions and in-depth reflections, aiming to lay the foundation and point out the direction for the future co-construction path of Guoyao Shengkang, which is of great significance for the strategic development of Guoyao Shengkang.
6month10On the day, the meeting held a brainstorming session focusing on two main themes: 'Track Selection' and 'Capability Building'. Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the meeting and made a detailed sharing on the analysis of China's healthcare innovation market. He also conducted an analysis of the current situation and trends in the innovative drug market, the innovative device market, as well as the development path of marketing and promotion under the new circumstances.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua first made a brief analysis of the current situation and trends in the innovative drug market, covering aspects such as the pharmaceutical market lifecycle, market size, drug treatment fields, new drug clinical trials, drug medical insurance negotiations, centralized drug procurement, capital market investment and financing. Development Trend of Antibody Drug InnovationCGTThe development trends of innovation, as well as nucleic acid drug innovation, are explored from multiple perspectives. He stated that overall, although there have been impacts from multiple rounds of price cuts in centralized procurement and medical insurance, considering favorable factors such as increased disease burden, population aging, improved payment capabilities and diversification of payment methods, as well as the increase in innovative varieties, the Chinese pharmaceutical industry will still maintain growth in the future.
Subsequently, Maohua then An analysis is conducted on the current market situation of innovative devices. He pointed out that in recent years, the state has continuously introduced favorable policies to promote the development of innovative medical devices. The normalization of centralized procurement of medical consumables has forced medical device companies to achieve breakthroughs through technological innovation. Favorable factors such as capital support, increased talent supply, and diversified cooperation models have also laid a solid foundation for the development of innovative medical devices in China. "China's medical device innovation started relatively late but has developed rapidly, gradually moving from imitation-based innovation to independent innovation. It is believed that it will further expand into the global market," said Mao Hua.
Finally, texturing The development path of marketing promotion under the new situation elaborates on the author's views. Faced with competition in centralized procurement and pressure on healthcare cost control, multinational pharmaceutical companies are accelerating the optimization of organizational structures, transformation of retail formats, and digital marketing in commercialization; local biotech companies are turning towards licensing cooperation.License-out of the Mainland), consignment sales/Cooperate with external partners or build our own teams to address the shortcomings in commercial capabilities through a multi-level model.
Mao Hua believes that enterprises need to conduct thorough research into the market capacity and relevant data of overseas regions, choose the outbound model and region based on their own circumstances, and implement localization execution strategies; do a good job in product positioning analysis and market analysis, make strategic layouts for the entire product lifecycle, adhere to long-termism and a global perspective, and build a systematic and international business system.
After the customization sharing session ended, the heads of member companies kept asking questions and engaging in exchanges. Representatives from various member companies all expressed that they now have a clearer understanding and awareness of the landscape of the medical innovation market.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
